Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.12 +1.50 (+1.48%)
Official Closing Price Updated: 4:10 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
96 97 Next >
3 Forever Stocks to Buy With $100
With $100 or less, you can buy at least one share of one of these top stocks. 
Via The Motley Fool
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
Exposures COVID-19
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
On Friday, Judge Thomas Rose, serving in the U.S. 
Via Benzinga
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
From Merck & Co., Inc.
Via Business Wire
Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors.
Why MERCK & CO. INC. (NYSE:MRK) should be investigated by quality investors. 
Via Chartmill
Merck & Co Inc. (NYSE: MRK) Highlighted for Surprising Price Action
Via Investor Brand Network
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
What 7 Analyst Ratings Have To Say About Merck & Co
Via Benzinga
Cannabis Industry's Capital Crunch: Why It Needs More Funds Than Other Industries, Will Fed Legalization Change This?
Recent research conducted by Viridian Capital Advisors reveals that the cannabis sector requires more capital as compared to other similar industries. 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Steady Eddies: 7 Unshakeable Stocks for Any Type of Market
With economic circumstances treading in uncertain waters, investors may want the confidence of safe stocks to buy. 
Via InvestorPlace
Better Pharma Growth Stock: Eli Lilly vs. Merck
This is a close contest, but there's a clear winner. 
Via The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the Citi 18th Annual BioPharma Conference
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Viridian Chart Of The Week: How Capital Intensive Is Cannabis?
The chart explores the capital intensity of cannabis compared to four other industries thought to be likely suitors for cannabis companies upon federal legalization: Tobacco, Alcoholic Beverages,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications
Some of the most frequently prescribed medications in the U.S. might soon become more affordable. 
Via Benzinga
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
Merck & Co Inc (NYSE: MRK) and Eisai Ltd (OTC: ESALY) provided an update on the Phase 3 LEAP-010 trial evaluating Keytruda (pembrolizumab), plus Lenvima for recurrent or metastatic head and neck... 
Via Benzinga
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
From Merck & Co., Inc.
Via Business Wire
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market
The company inked a new deal on Monday to test a new regimen using a second cancer vaccine. 
Via Investor's Business Daily
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.